ViewPoints: Biogen Idec moves swiftly to allay Tecfidera safety concerns – key opinion leaders in agreement
April 18, 2013 On Thursday, Biogen Idec delivered a positive Q1 conference call revising guidance upwards with revenue growth for…
How Does Tecfidera (BG-12) Compare With Other MS Drugs?
By Kathleen DohenyWebMD Health News Reviewed by Brunilda Nazario, MD April 25, 2013 – With the arrival of Tecfidera this spring, people withmultiple sclerosis now…
Stuart Schlossman
Oral MS Drug (Aubagio) Prevents Second Attacks
By John Gever, Deputy Managing Editor, MedPage Today Published: April 25, 2013 Patients diagnosed with clinically isolated syndrome after experiencing a…
Stuart Schlossman
Health Canada Approves TECFIDERA™ As A First-Line Oral Treatment For Multiple Sclerosis
TECFIDERA™, formerly BG-12, provides a combination of proven efficacy and favourable safety profile MISSISSAUGA, ON – April 9, 2013 –…
Stuart Schlossman
MS Patients on Oral Therapies Are More Optimistic About Their Disease, According to Kantar Health Survey
Oral disease-modifying drugs are recent additions to the multiple sclerosis market. New York, NY (PRWEB) April 03, 2013 Multiple sclerosis patients who are…
Stuart Schlossman
Biogen prices new MS drug at discount to key competitors
DISCOUNTED???? WASHINGTON (Reuters) – Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis…
Stuart Schlossman
Now approved—a new pill for relapsing forms of multiple sclerosis (MS)
Tecfidera was approved by the FDA for the treatment of people with relapsing forms of MS. Taking Tecfidera What you…
Stuart Schlossman
Biogen’s MS ORAL Drug Tecfidera (BG12) Wins FDA Nod
By John Gever, Senior Editor, MedPage Today Published: March 27, 2013 SILVER SPRING, Md. — Dimethyl fumarate has won FDA approval…
Stuart Schlossman
Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Up to seven years of clinical…
Stuart Schlossman
Decision Looms on New Multiple Sclerosis Drug
March 25, 2013 Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec (NASDAQ:BIIB )…
Stuart Schlossman
